Viewing Study NCT01729104

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 8:00 PM
Ignite Modification Date: 2026-01-22 @ 3:35 PM
Study NCT ID: NCT01729104
Status: TERMINATED
Last Update Posted: 2019-10-22
First Post: 2012-11-09
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Lymphoma View
None Mantle cell lymphoma View
None MCL View
None Relapsed View
None Refractory View
None Carfilzomib View
None Rituximab View
None Rituxan View
None Lenalidomide View
None CC-5013 View
None Revlimid View